Publications

In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): A fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group. by Jones RN and Erwin ME. published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 55-64

Activity of a broad-spectrum cephalosporin (RO 48-8391) alone and in combination with two novel β-lactamase inhibitors (RO 48-5545 and RO 48-8724). by Jones RN, Marshall SA and Varnam DJ published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 85-94

Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. by Jones RN, Biedenbach DJ, Marshall SA, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 107-110

Comparative antimicrobial activity of trovafloxacin tested against 3,049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. by Jones RN, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 119-126

Antimicrobial activity of gatifloxacin tested against 1,676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. by Jones RN, Beach ML, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (3): 247-252

Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp. and enterococci of animal and human origin. by Jones RN, Chen YS and Marshall SA published in Clin. Microbiol. Infect. 1998; 4 (10): 601-603

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin. by Johnson DM and Jones RN. published in J. Antimicrob. Chemother. 1998; 42 (4): 555-557

Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. by Johnson DM, Jones RN and Pfaller MA published in J. Antimicrob. Chemother. 1998; 42 (4): 557-559

Molecular analysis of TN1546 in Enterococcus faecium isolated from animals and humans. by Jensen LB, Ahrens P, Dons L, Jones RN, Hammerum AM and Aarestrup FM published in J. Clin. Microbiol. 1998; 36 (2): 437-442

International multicenter investigation of LB20304, a new fluoronaphthyridone. by Hohl AF, Frei R, Punter V, von Graevenitz A, Knapp C, Washington J, Johnson D and Jones RN published in Clin. Microbiol. Infect. 1998; 4 (5): 280-284

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Kugler K, Freeman J and Jones RN published in Clin. Infect. Dis. 1998; 27 (4): 764-770

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada – 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Erwin ME, Brueggemann AB and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 313-316

Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998). by DiPersio JR, Jones RN, Barrett T, Doern GV and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 131-135

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. by Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, and Jones RN published in Ir. J. Med. Sci. 1998; 167 (3): 155-159

Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight Gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. by Chen YS, Marshall SA, Winokur PL, Coffman SL, Wilke WW, Murray PR, Spiegel CA, Pfaller MA, Doern GV, and Jones RN published in J. Clin. Microbiol. 1998; 36 (10): 2996-3001

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. by Biedenbach DJ, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 349-353

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311

Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 135-137

Comparative evaluation of Etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria. by Marshall SA, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 93-97

Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. by Marco F, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (1): 55-57

Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria. by Marco F, Barrett MS and Jones RN published in J. Antimicrob. Chemother. 1997; 40 (4): 605-607

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. by Klepser ME, Wolfe EJ, Jones RN, Nightingale CH and Pfaller MA published in Antimicrob. Agents Chemother. 1997; 41 (6): 1392-1395

Antimicrobial activity of RU-66647, a new ketolide. by Jones RN and Biedenbach DJ. published in Diagn. Microbiol. Infect. Dis. 1997; 27(1-2): 7-12

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 21-28

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. by Jones RN, Barrett MS and Erwin ME published in Antimicrob. Agents Chemother. 1997; 41 (2): 488-493

A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. by Jones RN, Jacobs MR, Washington JA and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 75-83

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response. by Jones RN and Dudley MN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 5-18

Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods. by Jones RN, Marshall SA and Zerva L published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 35-40

Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results. by Jones RN, Barrett MS and Deguchi T published in Diagn. Microbiol. Infect. Dis. 1997; 28 (4): 193-200

Ofloxacin otic solution for treatment of otitis externa in children and adults. by Jones RN, Milazzo J and Seidlin M published in Arch. Otolaryngol. Head Neck Surg. 1997; 123 (11): 1193-1200

Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and the United States. by Jones RN, Marshall SA and Grimm H published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 87-94

Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. by Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 95-102

Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric Gram- negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. by Jones RN, Pfaller MA, Marshall SA, Hollis RJ and Wilke WW published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 187-192

Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. by Jones RN, Salazar JC, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 265-272

CQ-397 and CQ-414: Antimicrobial activity and spectrum of two fluoroquinolone—cephalosporin, dual-action compounds with carboxamido bonds. by Johnson DM and Jones RN. published in Clin. Microbiol. Infect. 1997; 3 (3): 335-344

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. by Jamjian C, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (2): 454-459

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. by Jamjian C, Barrett MS and Jones RN published in Diagn, Microbiol, Infect, Dis, 1997; 27 (4): 129-138

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria. by Gales AC, Pignatari AC, Jones RN, Baretta M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (2): 137-144

Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. by Gales AC, Bolmstrom A, Sampaio J, Jones RN and Sader HS published in Braz. J. Infect. Dis. 1997; 1 (4): 196-203

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates. by Flynn CM, Kelley CM, Barrett MS and Jones RN published in J. Clin. Microbiol. 1997; 35 (8): 2083-2086

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin. by Erwin ME, Varnam D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 93-100

Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. by Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN and Saubolle MA published in J. Clin. Microbiol. 1997; 35 (8): 2115-2119

A cluster of serious Escherichia coli infections in a neonatal intensive care unit. by Diekema DJ, Barr J, Boyken LD, Buschelman BJ, Jones RN, Pfaller MA and Herwaldt LA published in Infect. Control Hosp. Epidemiol. 1997; 18 (11): 774-776

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. by Cormican MG and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (1): 204-211

Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 241-248

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. by Biedenbach DJ, Schermer IH and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 1-5

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1997; 35 (12): 3198-3202